InstalabEarly Insulin Resistance Panel
Should you take a Early Insulin Resistance Panel test?
This test is most useful if any of these apply to you.
11 biomarkers included
- CardioIQ Insulin Resistance ScoreA proprietary composite score that combines fasting insulin and C-peptide into one estimate of insulin resistance.Why it mattersA single summary number that flags insulin resistance when individual markers sit in a gray zone.
- Intact InsulinMeasures biologically active insulin specifically, without cross-reacting with its inactive precursor, for a cleaner read of true insulin output.Why it mattersA more specific insulin measure that sharpens the picture of early compensatory overproduction.
- C-PeptideReleased alongside insulin in equal amounts, it gauges how much insulin the pancreas is actually producing.Why it mattersPreserved C-peptide with high resistance markers means beta cells are still compensating rather than failing.
- HOMA-IRPairs fasting insulin with glucose to estimate how hard your body is working to keep blood sugar normal.Why it mattersA rising score points to insulin resistance while glucose is still holding steady.
- TyG IndexCombines fasting triglycerides and glucose into a single, low-cost read of insulin resistance that also reflects the liver's handling of fat.Why it mattersA high value flags insulin resistance and metabolic syndrome risk, often before fasting glucose looks abnormal.
- GlucoseThe fasting blood-sugar anchor; it grounds the insulin-based indices and shows whether compensation is still keeping glucose controlled.Why it mattersRising glucose despite high insulin suggests the pancreas is losing the compensation battle.
- HbA1cReflects average blood sugar over about three months, smoothing out the day-to-day swings a single glucose reading misses.Why it mattersA creeping HbA1c signals that glucose control is slipping toward prediabetes over time.
- InsulinMeasures the fasting insulin your pancreas releases and feeds the HOMA-IR calculation; high levels signal early compensation for resistant tissues.Why it mattersHigh fasting insulin with normal glucose is the earliest sign your body is overworking to stay in range.
- ALTA liver enzyme that rises when fat accumulates in liver cells, a common companion to insulin resistance.Why it mattersElevated ALT hints at fatty liver, the hepatic face of insulin resistance.
- ASTA second liver enzyme that, read next to ALT, helps gauge liver stress linked to metabolic dysfunction.Why it mattersAST rising alongside ALT strengthens the case for fat-related liver involvement.
- TriglyceridesTracks the blood fat that climbs when insulin resistance drives the liver to overproduce fat-carrying particles.Why it mattersElevated triglycerides tend to rise in step with insulin resistance and feed the TyG calculation.
About Early Insulin Resistance Panel
Your body can be sliding toward type 2 diabetes for years while your blood sugar reads perfectly normal. The reason is insulin resistance: your cells stop responding well to insulin, so your pancreas simply makes more to keep glucose in check.
This panel is built to catch that hidden effort. By measuring blood sugar, the insulin behind it, and the fat and liver signals that travel with insulin resistance, it can show whether your metabolism is compensating quietly long before a standard glucose test would flag a problem.
What This Panel Reveals
No single number tells the full story of early metabolic trouble, so this panel reads three connected systems at once. The interpretation frameworks for the insulin-based markers are still evolving, but together they draw a clearer picture than any one test alone.
The blood-sugar markers, fasting glucose and HbA1c (your average blood sugar over roughly three months), show whether glucose is still under control. In early insulin resistance they often look normal, which is exactly why they can be falsely reassuring on their own.
The insulin markers reveal the effort behind that normal-looking glucose. Fasting insulin, C-peptide (a molecule released in step with insulin that reflects how much your pancreas is producing), and the calculated HOMA-IR score (a pairing of fasting insulin and glucose that estimates insulin resistance) expose compensatory overproduction. When insulin runs high to hold glucose steady, your insulin-making beta cells are working overtime. This kind of resistance can build years before glucose starts to climb.
The lipid and liver markers capture where insulin resistance spills over. The triglyceride-glucose index (TyG, a simple combination of fasting triglycerides and glucose) and triglycerides themselves reflect the liver overproducing fat, while the liver enzymes ALT and AST (proteins that leak into the blood when liver cells are stressed) can signal fat building up in the liver. In one large biobank study, TyG correctly flagged insulin resistance about 90% of the time (90% sensitivity) while keeping false alarms moderate (79% specificity), and pooled across screening studies it identified metabolic syndrome with roughly 80% sensitivity and 81% specificity.
How to Read Your Results Together
The value of this panel is in the pattern, not any one marker. Three combinations tell most of the early story, though in real bodies they often overlap rather than arrive in a strict sequence.
| Pattern | What It Suggests |
|---|---|
| High insulin, C-peptide and HOMA-IR with normal glucose and HbA1c | Compensated insulin resistance. Your pancreas is keeping sugar normal by working harder. |
| High TyG and triglycerides with rising ALT and AST | The lipid and liver arm of insulin resistance, often pointing toward fatty liver. |
| Glucose and HbA1c climbing while insulin and C-peptide no longer rise to match | Early beta-cell strain, where the compensation that held glucose steady is starting to fail. |
Read this way, the panel separates a body that is compensating well from one whose insulin factory is running down. That distinction is invisible to glucose and HbA1c alone, because both can look identical in each of these very different situations.
What to Do with Your Results
If the compensated pattern shows up, treat it as an early, actionable warning rather than a diagnosis. Insulin resistance responds strongly to changes in body composition, physical activity, sleep, and diet, and acting during this window is where prevention pays off. This is not only about diabetes: in a 16-year community study, people in the highest TyG group carried a 36% higher risk of cardiovascular disease.
If the liver enzymes or TyG stand out, a fatty-liver evaluation and a fuller lipid workup, including ApoB (a count of harmful cholesterol-carrying particles), are reasonable next steps. If glucose and HbA1c are drifting up, an oral glucose tolerance test and a conversation with a clinician about prediabetes are warranted. Because fasting insulin and HOMA-IR vary substantially from week to week, retest every three to six months rather than chasing small swings, and confirm a real trend across draws before acting on it.
When Results Can Be Misleading
Several factors move many of these markers at once. Most require a 10 to 12 hour fast, because recent food raises glucose, insulin, and triglycerides together and distorts the insulin-based indices. Acute illness, infection, hard exercise the day before, or short-term stress can transiently push insulin and liver enzymes higher. Normal liver enzymes also do not rule out fatty liver, since ALT and AST can read normal even when fat has already built up in the liver. Fasting insulin and HOMA-IR swing from day to day too, varying by roughly a quarter to a third within the same person (a within-person variation near 27 to 30%), so a single value is best read as one point in a trend, not a verdict.